Clinical Trials Showcase
Monday 5 October
- Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
- MRC OV05/EORTC 55955 Ovarian Cancer Trial of early treatment of relapse based on CA125 level alone versus delayed treatment
- Results from the MRC COIN trial of first-line therapy for advanced colorectal cancer (aCRC)
- Results of a phase III multi-centre randomised controlled trial of intensity modulated (IMRT) vs conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005)
